Sectors
CLDI
Calidi Biotherapeutics, Inc.
1.34
800 x 1.34
100 x 1.36
bid
ask
+
0.02
1.52%
450 @ 06:47 PM
1.36 +0.02 (1.49%)
| Ytd | -92.84% | |
| 1y | -94.92% |
1.31
day range
1.38
1.25
52 week range
27.84
| Open | 1.32 | Prev Close | 1.32 | Low | 1.31 | High | 1.38 | Mkt Cap | 3.46M |
| Vol | 36.38K | Avg Vol | 311.91K | EPS | -37.60 | P/E | N/A | Forward P/E | -1.57 |
| Beta | 0.57 | Short Ratio | 0.88 | Inst. Own | 2.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.87 | 200-d Avg | 8.95 | 1yr Est | 6.25 |
| Income Statement | |||
| Operating Expenses | 4.15M | ||
| Research and Development Expense | 2.56M | ||
| Selling, General and Administrative Expense | 1.59M | ||
| Operating Income | -4.15M | ||
| Interest Expense | 35.00K | ||
| Income Tax Expense | 5.00K | ||
| Net Income | -4.16M | ||
| Net Income Common Stock | -4.16M | ||
| Net Income Common Stock (USD) | -4.16M | ||
| Consolidated Income | -4.16M | ||
| Earnings per Basic Share | -2.94 | ||
| Earnings per Basic Share (USD) | -2.94 | ||
| Earnings per Diluted Share | -2.94 | ||
| Earning Before Interest & Taxes (EBIT) | -4.12M | ||
| Earning Before Interest & Taxes (USD) | -4.12M | ||
| Weighted Average Shares | 1.42M | ||
| Weighted Average Shares Diluted | 1.42M | ||
| Balance Sheet | |||
| Cash and Equivalents | 4.07M | ||
| Cash and Equivalents (USD) | 4.07M | ||
| Current Assets | 5.43M | ||
| Property, Plant & Equipment Net | 1.77M | ||
| Total Assets | 7.20M | ||
| Debt Current | 1.18M | ||
| Total Debt | 1.94M | ||
| Current Liabilities | 3.24M | ||
| Debt Non-Current | 766.00K | ||
| Total Liabilities | 4.07M | ||
| Accumulated Retained Earnings (Deficit) | -149.89M | ||
| Accumulated Other Comprehensive Income | -26.00K | ||
| Shareholders Equity | 3.13M | ||
| Shareholders Equity (USD) | 3.13M | ||
| Assets Non-Current | 1.78M | ||
| Total Debt (USD) | 1.94M | ||
| Liabilities Non-Current | 834.00K | ||
| Trade and Non-Trade Payables | 930.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 438.00K | ||
| Net Cash Flow from Financing | 1.83M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -2.56M | ||
| Capital Expenditure | -33.00K | ||
| Issuance (Purchase) of Equity Shares | 1.99M | ||
| Issuance (Repayment) of Debt Securities | -165.00K | ||
| Net Cash Flow from Investing | -33.00K | ||
| Net Cash Flow from Operations | -4.35M | ||
| Effect of Exchange Rate Changes on Cash | -3.00K | ||
| Share Based Compensation | 157.00K | ||